Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.

P. W. Nance, J. Bugaresti, K. Shellenberger, William Sheremata, Alberto Martinez-Arizala

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Tizanidine, an imidazoline that acts as an agonist at alpha 2-adrenergic receptors, has been shown to be effective in reducing spasticity caused by MS. This multicenter study (14 sites) assessed the efficacy and safety of oral tizanidine in patients who had spinal cord injury of > 12 months' duration. Of the 124 patients admitted to the study, 78 completed it. Tizanidine was titrated to an optimized dosage in each patient to a maximum of 36 mg/d. Muscle tone, assessed by Ashworth score, was significantly reduced (p = 0.0001) by tizanidine treatment in comparison with placebo. Video motion analysis of the pendulum test showed improvement in the tizanidine-treated patients vs placebo (p = 0.04) and showed a significant correlation with the Ashworth score (p < 0.001). No significant alterations in muscle strength or vital signs were noted in either treatment group. The most common adverse events during tizanidine treatment were somnolence, xerostomia, and fatigue. It was concluded that, overall, tizanidine is effective in reducing spasticity in patients with spinal cord injury.

Original languageEnglish
JournalNeurology
Volume44
Issue number11 Suppl 9
StatePublished - Nov 1 1994

Fingerprint

Spinal Cord Injuries
Safety
Therapeutics
Adrenergic alpha-2 Receptor Agonists
Placebos
Imidazolines
Xerostomia
Vital Signs
Muscle Strength
tizanidine
Multicenter Studies
Fatigue
Muscles

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. / Nance, P. W.; Bugaresti, J.; Shellenberger, K.; Sheremata, William; Martinez-Arizala, Alberto.

In: Neurology, Vol. 44, No. 11 Suppl 9, 01.11.1994.

Research output: Contribution to journalArticle

@article{6d8be78c4a8b4c61b6fd24ba130e1834,
title = "Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.",
abstract = "Tizanidine, an imidazoline that acts as an agonist at alpha 2-adrenergic receptors, has been shown to be effective in reducing spasticity caused by MS. This multicenter study (14 sites) assessed the efficacy and safety of oral tizanidine in patients who had spinal cord injury of > 12 months' duration. Of the 124 patients admitted to the study, 78 completed it. Tizanidine was titrated to an optimized dosage in each patient to a maximum of 36 mg/d. Muscle tone, assessed by Ashworth score, was significantly reduced (p = 0.0001) by tizanidine treatment in comparison with placebo. Video motion analysis of the pendulum test showed improvement in the tizanidine-treated patients vs placebo (p = 0.04) and showed a significant correlation with the Ashworth score (p < 0.001). No significant alterations in muscle strength or vital signs were noted in either treatment group. The most common adverse events during tizanidine treatment were somnolence, xerostomia, and fatigue. It was concluded that, overall, tizanidine is effective in reducing spasticity in patients with spinal cord injury.",
author = "Nance, {P. W.} and J. Bugaresti and K. Shellenberger and William Sheremata and Alberto Martinez-Arizala",
year = "1994",
month = "11",
day = "1",
language = "English",
volume = "44",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "11 Suppl 9",

}

TY - JOUR

T1 - Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.

AU - Nance, P. W.

AU - Bugaresti, J.

AU - Shellenberger, K.

AU - Sheremata, William

AU - Martinez-Arizala, Alberto

PY - 1994/11/1

Y1 - 1994/11/1

N2 - Tizanidine, an imidazoline that acts as an agonist at alpha 2-adrenergic receptors, has been shown to be effective in reducing spasticity caused by MS. This multicenter study (14 sites) assessed the efficacy and safety of oral tizanidine in patients who had spinal cord injury of > 12 months' duration. Of the 124 patients admitted to the study, 78 completed it. Tizanidine was titrated to an optimized dosage in each patient to a maximum of 36 mg/d. Muscle tone, assessed by Ashworth score, was significantly reduced (p = 0.0001) by tizanidine treatment in comparison with placebo. Video motion analysis of the pendulum test showed improvement in the tizanidine-treated patients vs placebo (p = 0.04) and showed a significant correlation with the Ashworth score (p < 0.001). No significant alterations in muscle strength or vital signs were noted in either treatment group. The most common adverse events during tizanidine treatment were somnolence, xerostomia, and fatigue. It was concluded that, overall, tizanidine is effective in reducing spasticity in patients with spinal cord injury.

AB - Tizanidine, an imidazoline that acts as an agonist at alpha 2-adrenergic receptors, has been shown to be effective in reducing spasticity caused by MS. This multicenter study (14 sites) assessed the efficacy and safety of oral tizanidine in patients who had spinal cord injury of > 12 months' duration. Of the 124 patients admitted to the study, 78 completed it. Tizanidine was titrated to an optimized dosage in each patient to a maximum of 36 mg/d. Muscle tone, assessed by Ashworth score, was significantly reduced (p = 0.0001) by tizanidine treatment in comparison with placebo. Video motion analysis of the pendulum test showed improvement in the tizanidine-treated patients vs placebo (p = 0.04) and showed a significant correlation with the Ashworth score (p < 0.001). No significant alterations in muscle strength or vital signs were noted in either treatment group. The most common adverse events during tizanidine treatment were somnolence, xerostomia, and fatigue. It was concluded that, overall, tizanidine is effective in reducing spasticity in patients with spinal cord injury.

UR - http://www.scopus.com/inward/record.url?scp=0028535071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028535071&partnerID=8YFLogxK

M3 - Article

C2 - 7970010

AN - SCOPUS:0028535071

VL - 44

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11 Suppl 9

ER -